Sunesis sinks on Phase III Qinprezo survival miss
This article was originally published in Scrip
Executive Summary
Sunesis Pharmaceuticals sank 78% to $1.46 per share on 6 October when the company said Qinprezo (vosaroxin) did not meet the Phase III VALOR clinical trial's primary endpoint of a statistically significant improvement in median overall survival compared with placebo.